Home  |  Contact

Cellosaurus LNCaP-abl (CVCL_4793)

[Text version]

Cell line name LNCaP-abl
Accession CVCL_4793
Resource Identification Initiative To cite this cell line use: LNCaP-abl (RRID:CVCL_4793)
Comments Characteristics: Established after 10 months of propagation of LNCaP in steroid-depleted medium.
Karyotypic information: Has lost chromosome Y.
Sequence variations Homozygous for AR p.Thr878Ala (c.2632A>G) (from parent cell line).
Heterozygous for MEN1 p.Tyr313Ter (c.939T>A) (from parent cell line).
Heterozygous for PIK3R1 p.Arg639Ter (c.1915C>T) (from parent cell line).
PTEN p.Lys6Argfs*4 (c.17_18delAA) (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0395 (LNCaP)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
Publications

PubMed=10496349; DOI=10.1038/sj.bjc.6690684
Culig Z., Hoffmann J., Erdel M., Eder I.E., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M.R., Parczyk K., Klocker H.
Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Br. J. Cancer 81:242-251(1999)

Cross-references
Other Wikidata; Q54902830
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number15